Umeå University Antibody Halts Prostate Cancer Spread in Preclinical Study

Q: How soon could this 'safer' prostate cancer antibody, mAbF11, begin its first human clinical trials?

It is not possible to say that mAbF11 could begin human trials soon, because no trial start date has been announced and the drug is still in the preclinical stage. The Umeå University team reported strong mouse-model results and described the antibody as a fully human candidate with a potentially safer profile than older TGFβ-pathway approaches. But Professor Maréne Landström also said important steps remain before patients can receive it, including additional safety work and regulatory clearance in Europe or the United States. In practical terms, the next hurdle is completing the preclinical package needed for an IND or equivalent clinical-trial application, including toxicology, pharmacokinetics, manufacturing and dosing data. Only after regulators accept that package could a Phase 1, first-in-human study begin. That means the earliest realistic window would usually be measured in many months rather than weeks. For oncology antibodies, moving from promising preclinical data to a first human trial often takes around 12 to 24 months, though it can be faster or slower depending on funding, manufacturing readiness, safety findings and regulatory feedback. The broader drug-development timeline is often much longer. So the best evidence-based answer is that mAbF11 is moving toward clinical development, but as of July 2026 it has not entered human testing, and there is no public timeline yet for when its first clinical trial will start.

2 articles · Updated · ScienceDaily · Jul 21

A fully human antibody developed by Umeå University researchers stopped both tumor growth and metastatic spread in aggressive, androgen-independent prostate cancer in preclinical tests.
The treatment targets a newly identified mechanism driving cancer cell growth, invasiveness and metastasis, which researchers say could also lower the risk of side effects.
The findings, published in Signal Transduction and Targeted Therapy, mark an early milestone rather than a patient-ready therapy; additional safety studies and regulatory approvals in Europe or the US are still required.
SciLifeLab drug-development specialists, Umeå Biotech Incubator and Umeå-based MetaCurUm Biotech AB helped develop and test the antibody.
Researchers now plan to test whether the same strategy can work against other solid tumors, aiming to improve survival and quality of life in advanced cancer.

Sources

ScienceDaily17h ago

Umeå University Antibody Drug Halts Aggressive Prostate Cancer Spread

Medical Daily6h ago

Umeå University Researchers Develop Antibody Blocking Aggressive Prostate Cancer Growth in Preclinical Models

How soon could this 'safer' prostate cancer antibody, mAbF11, begin its first human clinical trials?

Can this new Swedish antibody challenge existing treatments in the crowded $8 billion prostate cancer market?

What is the greatest hurdle this new cancer antibody must overcome to succeed in human trials?

New Fully Human Antibody mAbF11 Blocks Metastasis in Aggressive Prostate Cancer: Mechanism, Promise, and Next Steps

Overview

Researchers at Umeå University and their international partners have developed a fully human monoclonal antibody, mAbF11, that shows strong promise in preclinical models for treating aggressive, castration-resistant prostate cancer. This antibody is designed to specifically target and halt both tumor growth and the spread of metastases, offering new hope for patients with this challenging disease. Its fully human composition reduces the risk of immune rejection and adverse reactions, making it safer and more compatible with the human body. The success of mAbF11 in laboratory studies marks a significant step forward in the search for more effective and safer cancer therapies.

...